MarketBeat
09 May 2026, 08:07 UTC · 18w ago
Verdict
Headline takes no side. We score XENE +1.00 across five claims — strongly bullish.
+1.00strongly bullish
More positive than 98% of ticker scores this week
What the story claims
5 claims · scored −1 bearish … +1 bullish
Xenon's Phase 3 X-TOLE2 study in focal onset seizures met its primary endpoint, demonstrating what the company believes is the highest placebo-adjusted median percent reduction ever seen in a pivotal FOS study.
More positive than 99% of claims this week
Xenon plans to submit a new drug application to the FDA for azetukalner in the third quarter of 2026, targeting a potential launch at the end of 2027 or early 2028.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More positive than 97% of claims this week
Xenon ended the first quarter with $1.3 billion in cash, significantly boosting its runway into 2029 to support a U.S. launch and multiple registrational programs.
So whatA fortified balance sheet removes near-term financing dilution risk and fully funds the company through key pipeline milestones and commercialization.
More positive than 96% of claims this week
Long-term open-label extension data showed patients treated for at least 48 months had a 91% reduction in monthly seizure frequency, with nearly 40% seizure-free for at least 12 months.
More positive than 91% of claims this week
Xenon is advancing azetukalner in major depressive disorder and bipolar depression with three Phase 3 studies, expecting top-line results from X-NOVA2 in the first half of 2027.
More positive than 84% of claims this week
Which stocks this story touches
More positive than 98% of ticker scores this week
Positive Phase 3 data for azetukalner, a clear path toward FDA submission, and a strengthened cash runway into 2029.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Business Wire
1d ago
−29.5%
Price is moving against the score
$39.77 vs $56.44 close before publication (May 8) · not market-adjusted
XENE chart →
